Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roivant gets rights to Poxel's imeglimin worldwide except in certain Asian countries

Executive Summary

Poxel SA licensed Roivant Sciences GMBH rights to develop and commercialize its Type II diabetes compound imeglimin in the US, Europe, and all other countries except certain Asian territories where Poxel's partner Sumitomo Dainippon Pharma has rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • Intra-Biotech Deal

Related Companies